Acyl
CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA
Desaturase or SCD or EC 1.14.19.1) - Stearoyl-CoA desaturase 1 is a protein
encoded by the SCD gene. Stearoyl-CoA desaturase-1 plays an important enzyme in
fatty acid metabolism. Alteration in SCD1 expression changes the fatty acid
profile of these lipids and produces diverse effects on cellular function.
High
SCD1 expression is correlated with metabolic diseases such as obesity and
insulin resistance, whereas low levels are protective against these metabolic
disturbances. SCD1 is also involved in the regulation of inflammation and
stress in distinct cell types, including?-cells, adipocytes, macrophages,
endothelial cells, and myocytes. Complete loss of SCD1 expression has been
implicated in liver dysfunction and several inflammatory diseases such as
dermatitis, atherosclerosis, and intestinal colitis.
Acyl
CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA
Desaturase or SCD or EC 1.14.19.1)
pipeline Target constitutes close to 5 molecules. The molecules developed by
companies in Phase III, Preclinical, Discovery and Unknown stages are 1, 2, 1
and 1 respectively. Report covers products from therapy areas Gastrointestinal,
Oncology and Central Nervous System which include indications Non-Alcoholic
Steatohepatitis (NASH), Colorectal Cancer, Liver Fibrosis, Metastatic Renal
Cell Carcinoma, Non Alcoholic Fatty Liver Disease (NAFLD) and Osteoarthritis
Pain.
The
latest report Acyl CoA Desaturase - Pipeline Review, H1 2018, outlays
comprehensive information on the Acyl CoA Desaturase (Fatty Acid Desaturase or
Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted
therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. It
also reviews key players involved in Acyl CoA Desaturase (Fatty Acid Desaturase
or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1)
targeted therapeutics development with respective active and dormant or
discontinued projects.
The
report is built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources.
The
report provides a snapshot of the global therapeutic landscape for Acyl CoA
Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA
Desaturase or SCD or EC 1.14.19.1)
The
report reviews Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase
or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted therapeutics under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which includes,
product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in Acyl CoA Desaturase (Fatty Acid
Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC
1.14.19.1) targeted therapeutics and enlists all their major and minor projects
The
report assesses Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9
Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) targeted
therapeutics based on mechanism of action (MoA), route of administration (RoA)
and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to Acyl CoA Desaturase (Fatty Acid
Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC
1.14.19.1) targeted therapeutics
To know, more click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204
No comments:
Post a Comment